The 11th national VBP in 2025H1 will impact big pharma companies. AK112 would seize 40%-50% of the PD-1/VEGF BsAb market. MIXUE's IPO debut was strong, but with potential for share price corrections.
What is covered in the Full Insight:
Introduction
11th National VBP Impact
PD-1/L1 x VEGF BsAb Market Analysis
MIXUE’s IPO Performance
Market Review and Risk Disclosure
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
Unlock research summaries
Follow top, independent analysts
Receive personalised alerts
Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.